Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about PRLD, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| SMARCA2 Degrader PRT3789 | Advanced Solid Tumor | Phase 2 · NCT06682806 | Terminated |
| Myeloid Cell Leukemia 1 Inhibitor PRT1419 | Acute Myeloid Leukemia | Phase 1 · NCT05107856 | Terminated |
| Zanubrutinib | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) | Phase 1 · NCT05665530 | Completed |
| PRMT5 Inhibitor PRT811 | Advanced Solid Tumor | Phase 1 · NCT04089449 | Completed |
| SMARCA2 Degrader PRT7732 | Advanced Solid Tumor | Phase 1 · NCT06560645 | Terminated |
| Protein Arginine Methyltransferase 5 Inhibitor… | Relapsed/Refractory Advanced Solid Tumors | Phase 1 · NCT03886831 | Completed |
| CDK4/6 Inhibitor PRT3645 | Breast Cancer | Phase 1 · NCT05538572 | Completed |
| CDK9 Inhibitor PRT2527 | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) | Phase 1 · NCT05665530 | Completed |
| PRT13722 | Breast Cancer | Phase 1 · NCT07905001 | Recruiting |
| JAK2V617F Inhibitor PRT12396 | Polycythemia Vera (PV) | Phase 1 · NCT07469891 | Recruiting |
| Imlunestrant | Breast Cancer | Phase 1 · NCT07905001 | Recruiting |
Also used in these trials (approved or third-party drugs, not PRLD's own candidates): Pembrolizumab, Venetoclax, Abemaciclib, Fulvestrant, Docetaxel Anhydrous, Azacitidine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
PRLD holds $151.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $18.6M/quarter from operations, an estimated runway of 24.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 39 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PRLD files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Baker Bros. Advisors LP | Institution (13G, 5%+) | 10,295,301 | 12.86% | 2026-04-20 |
| Krishna Vaddi CEO, Director · +837,000 options |
Insider | 6,745,647 | 8.42% | 2025-12-31 |
| RA CAPITAL MANAGEMENT, L.P. 10% owner · +1.41M options |
Insider | 6,475,882 | 8.09% | 2026-04-27 |
| Soleus Capital Management, L.P. | 5%+ holder (13G) | 3,378,378 | 4.22% | 2026-04-21 |
| David P Bonita Director, 10% owner · +76,000 options |
Insider | 526,300 | 0.66% | 2026-04-21 |
| ORBIMED ADVISORS LLC Director, 10% owner Includes shares also reported by David P Bonita, counted once |
Insider | 526,300 | 0.66% | 2026-04-21 |
| Andrew Combs Chief Chemistry Officer · +405,000 options |
Insider | 480,123 | 0.60% | 2025-03-25 |
| Sean P. Brusky Chief Business Officer |
Insider | 100,000 | 0.12% | 2026-03-05 |
| Jane Huang President, CMO · +218,750 options |
Insider | 86,917 | 0.11% | 2025-10-04 |
Share count 80,070,666 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PRLD and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →